evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

21 questions · 21 findings · 1 reviews · Stroke

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 6 · 28.6%GRADE not reported 0 · 0%Very low 1 · 4.8%Low 2 · 9.5%Moderate 5 · 23.8%High 7 · 33.3%

Summary of findings table ‐ Platelet transfusion vs open control

Death or dependence (mRS 4 to 6) at day 90 · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use

Summary of findings table ‐ Platelet transfusion probably leads to higher death or dependence (mRS 4–6) compared with open control (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Platelet transfusion vs open control

Intracerebral haemorrhage expansion by 24 hours · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use

Summary of findings table ‐ Platelet transfusion showed no clear difference in intracerebral haemorrhage expansion by 24 hours compared with open control (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Platelet transfusion vs open control

All serious adverse events · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use

Summary of findings table ‐ Platelet transfusion showed no clear difference in all serious adverse events compared with open control (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Platelet transfusion vs open control

Death from any cause · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use

Summary of findings table ‐ Platelet transfusion showed no clear difference in death from any cause compared with open control (moderate certainty).

1 finding from 1 review

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo/open control

All serious adverse events · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in all serious adverse events compared with placebo/open control (high certainty).

1 finding from 1 review

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo/open control

Death from any cause · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in death from any cause compared with placebo/open control (high certainty).

1 finding from 1 review

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo/open control

Death or dependence (mRS 4 to 6) at day 90 · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in death or dependence (mRS 4–6) compared with placebo/open control (high certainty).

1 finding from 1 review

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo/open control

Intracerebral haemorrhage expansion by 24 hours · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Antifibrinolytic drug(s) leads to lower intracerebral haemorrhage expansion by 24 hours compared with placebo/open control (high certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control

Death or dependence (mRS 4 to 6) at day 90 · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in death or dependence (mRS 4–6) compared with placebo/open control (low certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control

Intracerebral haemorrhage expansion by 24 hours · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in intracerebral haemorrhage expansion by 24 hours compared with placebo/open control (low certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control

All serious adverse events · adults with acute spontaneous intracerebral haemorrhage

It is very uncertain whether summary of findings table ‐ Recombinant activated factor VII changes all serious adverse events compared with placebo/open control (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control

Death from any cause · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in death from any cause compared with placebo/open control (moderate certainty).

1 finding from 1 review